Journal of the Korean Medical Association (대한의사협회지)

Korean Medical Association (대한의사협회)
권호 표지
DOI QR코드

DOI QR Code

Diagnosis and treatment of osteoporosis

골다공증의 진단과 치료

  • Park, Ye-Soo (Department of Orthopedic Surgery, Guri Hospital, Hanyang University College of Medicine)
  • 박예수 (한양대학교 의과대학 구리병원 정형외과)
  • Published : 2012.11.10
⟨ Previous Next ⟩

Abstract

Osteoporosis is a common bone disease in postmenopausal women that leads to an increased risk of fracture. In osteoporosis, the bone mineral density (BMD) is reduced, and bone micro- and macroarchitecture deteriorates. Osteoporosis is defined by the World Health Organization as a BMD of 2.5 standard deviations or more below the mean peak bone mass (average of young and healthy adults) as measured by dual energy X-ray absorptiometry (DEXA). Diagnosis of osteoporosis can be made using BMD measurement. The most popular method of measuring BMD is DEXA. In treatment, we can use various exercises and nutritional supplementation, medications, and lifestyle modification for the prevention of fractures.

Keywords

References

  1. Bartl R, Frisch B. Informed dicisions: osteoporosis. Heidelberg: Springer-Verlag Berlin; 2004. 253 p.
  2. Shin CS, Choi HJ, Kim MJ, Kim JT, Yu SH, Koo BK, Cho HY,Cho SW, Kim SW, Park YJ, Jang HC, Kim SY, Cho NH.Prevalence and risk factors of osteoporosis in Korea: acommunity-based cohort study with lumbar spine and hipbone mineral density. Bone 2010:47:378-387. https://doi.org/10.1016/j.bone.2010.03.017
  3. Kanis JA, Hans D, Cooper C, Baim S, Bilezikian JP, Binkley N, Cauley JA, Compston JE, Dawson-Hughes B, El-Hajj Fuleihan G, Johansson H, Leslie WD, Lewiecki EM, Luckey M, Oden A, Papapoulos SE, Poiana C, Rizzoli R, Wahl DA, McCloskey EV. Task Force of the FRAX Initiative. Interpretation and use of FRAX in clinical practice. Osteoporos Int 2011;22:2395-2411. https://doi.org/10.1007/s00198-011-1713-z
  4. Eastell R, Hannon RA. Biomarkers of bone health and osteoporosisrisk. Proc Nutr Soc 2008;67:157-162. https://doi.org/10.1017/S002966510800699X
  5. Fleisch HA. Bisphosphonates: preclinical aspects and use inosteoporosis. Ann Med 1997;29:55-62. https://doi.org/10.3109/07853899708998743
  6. Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD,Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, SantoraAC, Liberman UA; Alendronate Phase III OsteoporosisTreatment Study Group. Ten years' experience with alendroatefor osteoporosis in postmenopausal women. N Engl JMed 2004;350:1189-1199. https://doi.org/10.1056/NEJMoa030897
  7. Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T,Hochberg MC, Nevitt MC, Suryawanshi S, Cummings SR;Fracture Intervention Trial. Fracture risk reduction with alendronatein women with osteoporosis: the Fracture InterventionTrial. FIT Research Group. J Clin Endocrinol Metab2000;85:4118-4124. https://doi.org/10.1210/jc.85.11.4118
  8. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S,Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L,Wehren LE, Lombardi A, Santora AC, Cummings SR; FLEXResearch Group. Effects of continuing or stopping alendronateafter 5 years of treatment: the Fracture Intervention TrialLong-term Extension (FLEX): a randomized trial. JAMA2006;296:2927-2938. https://doi.org/10.1001/jama.296.24.2927
  9. Reid DM, Hosking D, Kendler D, Brandi ML, Wark JD,Marques-Neto JF, Weryha G, Verbruggen N, Hustad CM,Mahlis EM, Melton ME. A comparison of the effect of alendronateand risedronate on bone mineral density in postmenopausalwomen with osteoporosis: 24-month results fromFACTS-International. Int J Clin Pract 2008;62:575-584. https://doi.org/10.1111/j.1742-1241.2008.01704.x
  10. Silverman SL, Watts NB, Delmas PD, Lange JL, Lindsay R.Effectiveness of bisphosphonates on nonvertebral and hipfractures in the first year of therapy: the Risedronate andAlendronate (REAL) cohort study. Osteoporos Int 2007;18:25-34. https://doi.org/10.1007/s00198-006-0274-z
  11. Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000;11:83-91. https://doi.org/10.1007/s001980050010
  12. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T,Keller M, Chesnut CH 3rd, Brown J, Eriksen EF, Hoseyni MS,Axelrod DW, Miller PD. Effects of risedronate treatment onvertebral and nonvertebral fractures in women with postmenopausalosteoporosis: a randomized controlled trial. VertebralEfficacy with Risedronate Therapy (VERT) Study Group. JAMA1999;282:1344-1352. https://doi.org/10.1001/jama.282.14.1344
  13. Mellstrom DD, Sorensen OH, Goemaere S, Roux C, Johnson TD, Chines AA. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 2004;75:462-468. https://doi.org/10.1007/s00223-004-0286-7
  14. Younes H, Farhat G, el-Hajj Fuleihan G. Efficacy and tolerability of cyclical intravenous pamidronate in patients with low bone mass. J Clin Densitom 2002;5:143-149. https://doi.org/10.1385/JCD:5:2:143
  15. Delmas PD, Adami S, Strugala C, Stakkestad JA, Reginster JY,Felsenberg D, Christiansen C, Civitelli R, Drezner MK, ReckerRR, Bolognese M, Hughes C, Masanauskaite D, Ward P,Sambrook P, Reid DM. Intravenous ibandronate injections inpostmenopausal women with osteoporosis: one-year resultsfrom the dosing intravenous administration study. ArthritisRheum 2006;54:1838-1846. https://doi.org/10.1002/art.21918
  16. Eisman JA, Civitelli R, Adami S, Czerwinski E, Recknor C,Prince R, Reginster JY, Zaidi M, Felsenberg D, Hughes C,Mairon N, Masanauskaite D, Reid DM, Delmas PD, ReckerRR. Efficacy and tolerability of intravenous ibandronate injectionsin postmenopausal osteoporosis: 2-year results from theDIVA study. J Rheumatol 2008;35:488-497.
  17. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, CauleyJA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C,Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T,Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR;HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acidfor treatment of postmenopausal osteoporosis. N Engl J Med2007;356:1809-1822. https://doi.org/10.1056/NEJMoa067312
  18. Gasser JA, Ingold P, Venturiere A, Shen V, Green JR. Long-term protective effects of zoledronic acid on cancellous and cortical bone in the ovariectomized rat. J Bone Miner Res 2008;23:544-551.
  19. Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, PieperCF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L,Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK,Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S;HORIZON Recurrent Fracture Trial. Zoledronic acid and clinicalfractures and mortality after hip fracture. N Engl J Med2007;357:1799-1809. https://doi.org/10.1056/NEJMoa074941
  20. Sorensen HT, Christensen S, Mehnert F, Pedersen L,Chapurlat RD, Cummings SR, Baron JA. Use of bisphosphonatesamong women and risk of atrial fibrillation and flutter:population based case-control study. BMJ 2008;336:813-816. https://doi.org/10.1136/bmj.39507.551644.BE
  21. Yamashita J, McCauley LK. Antiresorptives and osteonecrosis of the jaw. J Evid Based Dent Pract 2012;12(3 Suppl):233-247. https://doi.org/10.1016/S1532-3382(12)70046-5
  22. Abrahamsen B, Eiken P, Eastell R. Subtrochanteric and diaphysealfemur fractures in patients treated with alendronate: aregister-based national cohort study. J Bone Miner Res 2009;24:1095-1102. https://doi.org/10.1359/jbmr.081247
  23. McClung MR, Miller PD, Brown JP, Zanchetta J, Bolognese MA, Benhamou CL, Balske A, Burgio DE, Sarley J, McCullough LK, Recker RR. Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet. Osteoporos Int 2012;23:267-276. https://doi.org/10.1007/s00198-011-1791-y
  24. Hodges LA, Connolly SM, Winter J, Schmidt T, Stevens HN, Hayward M, Wilson CG. Modulation of gastric pH by a buffered soluble effervescent formulation; a possible means of improving gastric tolerability of alendronate. Int J Pharm 2012;432:57-62. https://doi.org/10.1016/j.ijpharm.2012.04.073
  25. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, NickelsenT, Genant HK, Christiansen C, Delmas PD, Zanchetta JR,Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S,Ensrud KE, Avioli LV, Lips P, Cummings SR. Reduction of vertebralfracture risk in postmenopausal women with osteoporosistreated with raloxifene: results from a 3-year randomizedclinical trial. Multiple Outcomes of Raloxifene Evaluation(MORE) Investigators. JAMA 1999;282:637-645. https://doi.org/10.1001/jama.282.7.637
  26. Siris ES, Harris ST, Eastell R, Zanchetta JR, Goemaere S, Diez-Perez A, Stock JL, Song J, Qu Y, Kulkarni PM, Siddhanti SR,Wong M, Cummings SR; Continuing Outcomes Relevant toEvista (CORE) Investigators. Skeletal effects of raloxifene after8 years: results from the Continuing Outcomes Relevant toEvista (CORE) study. J Bone Miner Res 2005;20:1514-1524. https://doi.org/10.1359/JBMR.050509
  27. Silverman SL, Christiansen C, Genant HK, Vukicevic S, Zanchetta JR, de Villiers TJ, Constantine GD, Chines AA. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis; results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res 2008;23:1923-1934. https://doi.org/10.1359/jbmr.080710
  28. Dempster DW, Cosman F, Parisien M, Shen V, Lindsay R. Anabolic actions of parathyroid hormone on bone. Endocr Rev 1993;14:690-709.
  29. Canalis E, Giustina A, Bilezikian JP. Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 2007;357:905-916. https://doi.org/10.1056/NEJMra067395
  30. Jolette J, Wilker CE, Smith SY, Doyle N, Hardisty JF, Metcalfe AJ, Marriott TB, Fox J, Wells DS. Defining a noncarcinogenic dose of recombinant human parathyroid hormone 1-84 in a 2-year study in Fischer 344 rats. Toxicol Pathol 2006;34:929-940. https://doi.org/10.1080/01926230601072301

Cited by

  1. The Effects of Phlomis umbrosa Turcz on Osteoclast Differentiation vol.26, pp.3, 2012, https://doi.org/10.11637/kjpa.2013.26.3.115
  2. Customized Treatment for the Prevention of Osteoporotic Fracture vol.21, pp.4, 2012, https://doi.org/10.4184/jkss.2014.21.4.194
  3. 흰 무궁화 꽃 추출물의 항산화 활성과 골 흡수의 억제 효과 vol.23, pp.3, 2015, https://doi.org/10.7783/kjmcs.2015.23.3.190
  4. 이중에너지 방사선흡수 골밀도 장치의 품질관리 현황 vol.39, pp.4, 2012, https://doi.org/10.17946/jrst.2016.39.4.06
  5. 여대생의 체질량지수와 식습관에 따른 골밀도 비교 vol.40, pp.4, 2012, https://doi.org/10.17946/jrst.2017.40.4.07
  6. 리그난의 화학적 특성, 인체 건강에 미치는 영향 및 리그난의 우유 기능 강화에 관한 연구 고찰 vol.36, pp.2, 2018, https://doi.org/10.22424/jmsb.2018.36.2.81
  7. 불용성 골감소증을 동반한 손목골절환자의 각변형에 대한 증례 보고 vol.35, pp.4, 2012, https://doi.org/10.14406/acu.2018.027
  8. Effect of Training and Testing Condition of Convolutional Neural Network on evaluating Osteoporosis vol.43, pp.3, 2012, https://doi.org/10.17779/kaomp.2019.43.3.001
  9. 종설 : 치과위생사가 알아야 할 골다공증과 골 관련 사이토카인 vol.3, pp.2, 2020, https://doi.org/10.22753/jkdhs/2020.3.2.59